Back to Results

Bioatla Inc (BCAB)

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing selective antibody-based therapeutics for solid tumor cancers. Its pipeline includes mecbotamab vedotin (BA3011), a conditionally active biologic antibody-drug conjugate being studied in undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftamab vedotin (BA3021), which is being developed for melanoma and squamous cell carcinoma of the head and neck. The company is also advancing Evalstotug (BA3071) for several tumor types, along with additional candidates such as BA3182, BA3361, BA3142, and a preclinical CAB-Nectin 4 x CAB-CD3 program. Founded in 2007, BioAtla is headquartered in San Diego, California. The company’s common stock is listed on NASDAQ under the ticker BCAB.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-BCAB
$4.94
34.7% Upside
Undervalued
$500 13,524.0% Upside
—
Bargain
Weak
—
—
—
0.0%
August 5, 2026
-0.1x
-0.2x
3.1x
6.141 M
10.39 M
49.8%
82.6%
-111.6
—
73.5%
Valuation • Fair Value

Bioatla Inc (NASDAQ-BCAB) Fair Value by Valuation Model

Compare the primary fair value estimate for Bioatla Inc (NASDAQ-BCAB) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$4.94

Estimated upside of 34.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.64

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$5.13

Comparable-company valuation reference.

Analyst Price Target

$500 13,524.0% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Bioatla Inc (NASDAQ-BCAB) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Bioatla Inc (NASDAQ-BCAB)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2 M

Current operating scale indicator.

Revenue Forecast

2 M

Forward revenue estimate.

EBITDA

-49.589 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Bioatla Inc (NASDAQ-BCAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bioatla Inc (NASDAQ-BCAB)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-111.6

Lower score that deserves closer risk review.

FCF / Net Income

73.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bioatla Inc (NASDAQ-BCAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bioatla Inc (NASDAQ-BCAB)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Bioatla Inc (NASDAQ-BCAB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Bioatla Inc (NASDAQ-BCAB) Stock Forecast & Technical Outlook

Review Bioatla Inc (NASDAQ-BCAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Bioatla Inc (NASDAQ-BCAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Bioatla Inc (NASDAQ-BCAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Bioatla Inc (NASDAQ-BCAB) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Bioatla Inc (NASDAQ-BCAB) Stock FAQ

Quick answers about Bioatla Inc (NASDAQ-BCAB) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$4.94
Estimated upside 34.7%
Valuation Rating
Undervalued
Estimated upside of 34.7%
Analyst Target
$500 13,524.0% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Bioatla Inc (NASDAQ-BCAB) is $4.94. This implies an estimated upside of 34.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 34.7% versus the current market price.

The available analyst price target for Bioatla Inc (NASDAQ-BCAB) is $500 13,524.0% Upside.

The current financial health read for Bioatla Inc (NASDAQ-BCAB) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bioatla Inc (NASDAQ-BCAB) is August 5, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Bioatla Inc (NASDAQ-BCAB) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Bioatla Inc is 6.141 M.

The current enterprise value listed for Bioatla Inc is 10.39 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bioatla Inc is NASDAQ-BCAB, and the stock is listed on NASDAQ.

Bioatla Inc (NASDAQ-BCAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Bioatla Inc is 49.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bioatla Inc is 82.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)